What this means
This study is checking whether blood and spinal fluid tests, memory tests, and lifestyle questions can help diagnose Alzheimer's and related diseases. It has not yet reported results, so it cannot show whether these tests work.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 45 and over
- Where
- 1 site, including District of Columbia
The science
- Registered title
- DC Longitudinal Study on Aging and Specimen Bank
- Trial ID
- NCT03702907 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Aging, Aging Disorder
- Sponsor
- Georgetown University
- Ages
- 45 Years to no maximum
- Dates
- First posted Oct 11, 2018 · updated Oct 24, 2019
Registry summary
The Georgetown University Memory Disorders Program, part of the Department of Neurology, is conducting pilot studies of the feasibility of various diagnostic tests for Alzheimer's disease, mild cognitive impairment and other neurodegenerative diseases. Further, this study is assessing longitudinal changes in biological, lifestyle, and cognitive assessment collection.
The primary goal of this study is to examine the feasibility of biochemical assays, genetic testing, and cognitive and lifestyle assessments in the ante-mortem diagnosis of Alzheimer's disease, mild cognitive impairment and other neurodegenerative diseases. This research involves genetic and cognitive status testing but the findings will not be shared with research subjects. This will be accomplished ex vivo using blood, and/or cerebrospinal fluid (CSF) specimens from patients with a diagnosis of probable Alzheimer's disease, mild cognitive impairment, or other neurodegenerative diseases and from normal controls.
Sites (1)
- Georgetown University Memory Disorders Program, Washington D.C., District of Columbia, United States